123 results about "Neuritis" patented technology

The invention relates to the technical field of medicines, and discloses application of D-mannose in prevention and treatment of androgenetic alopecia. In the prior art, D-mannose can be a potential strategy for treating ferroptosis related diseases, can also be a non-prescription medicine supplement with high safety, and is used for treating neuritis diseases such as multiple sclerosis. The androgenic alopecia mouse model is constructed by utilizing dihydrotestosterone induction, the model mouse is subjected to mannose intervention, and the result shows that application of mannose can promote mouse hair growth, increase cortex thickness, promote hair regeneration and melanogenesis and effectively resist alopecia caused by dihydrotestosterone. The invention provides a new effect of mannose in prevention and treatment of androgenetic alopecia, and also provides a new strategy for prevention and treatment of androgenetic alopecia.

The invention belongs to the field of biological medicine, and provides preparation of a targeting hepcidin biological agent and application of the targeting hepcidin biological agent in relieving neuropathic pain. According to the invention, a new analgesic target, namely, Hamp, in the spinal cord is found for the first time, and the Hamp is abnormally highly expressed in the spinal cord of a pain model rat. A small interfering RNA (siRNA) targeting Hamp is designed, when the substance is applied to the spinal cord, cell ferroptosis and neuroinflammation in the spinal cord of a rat can be remarkably inhibited, and the substance has a remarkable analgesic effect on mechanical pain sensitivity and crymodynia sensitivity.

Provided are a polylactic acid and a use of a copolymer thereof in the preparation of a drug for promoting nerve growth and repair. The molecular weight of the polylactic acid and the copolymer thereof is 400-300 k Da. The drug has the following effects: 1) promoting the growth of nerve cells and nervous tissue; 2) promoting repair of nerve cells and nervous tissue; and 3) treating or preventing a peripheral nerve injury, a spinal cord injury, peripheral neuropathy, and neuritis. The molecular weight is preferably 5000-100 k Da. It is found for the first time that the polylactic acid and the copolymer thereof have a protective effect on nerves, and can promote nerve growth and a nerve injury repair.

The invention provides an extraction and detection method of a day lily active matter and application of the day lily active matter in anti-neuritis. Hemerocallis fulva contains various bioactive substances including flavone, polysaccharide and saponin, and the substances have potential application value in the fields of medicines and health care products. The invention provides a method for extracting the active components step by step, and rapid identification and detection are carried out by utilizing technologies such as fluorescence and ultraviolet-visible spectrophotometry. In addition, the invention also develops a detection method for evaluating the anti-neuritis effect of the active substances. Lipopolysaccharide (LPS) is used for stimulation to establish an inflammation model, day lily active substances are added, and the active substances are found to be capable of remarkably inhibiting generation and release of inflammatory factors and promoting growth and differentiation of neurons. Scientific basis is provided for developing new neuritis treatment methods, related drugs and the like.

The invention provides an application of polylactic acid and a copolymer thereof in preparation of a medicine for promoting nerve growth and repairing, the molecular weight of the polylactic acid and the copolymer thereof is 400-300k Da, and the medicine has the following effects: 1) promoting growth of nerve cells and nerve tissues; 2) promoting the repair of nerve cells and nerve tissues; 3) treating or preventing peripheral nerve injury, spinal cord injury, peripheral neuropathy and neuritis; preferably, the molecular weight is in the range of 5000 to 100 k Da. The invention discovers that polylactic acid and the copolymer thereof have a protection effect on nerves for the first time, and can promote growth of the nerves and repair of nerve injury.

The present application relates to novel substituted heterocyclic carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and / or prevention of diseases and to their use for producing medicaments for the treatment and / or prevention of diseases, in particular for the treatment and / or prevention of breathing difficulties including sleep-induced breathing difficulties such as central and obstructive sleep apnoea, snoring (primary and obstructive snoring), dysphagia, peripheral and cardiac vascular disorders including diabetic microangiopathies and disorders of the peripheral and central nervous system including neurodegenerative and neuroinflammatory disorders.

The present invention belongs to the technical field of biomedicine, and particularly relates to the use of a divalent metal lactate in the preparation of a product for preventing, improving, repairing and treating nerve damage. Preferably, the divalent metal lactate comprises one of or a combination of more than one of calcium lactate, magnesium lactate, zinc lactate and ferrous lactate. Provided in the present invention is a new treatment method for repairing central and peripheral nerve damage. The new treatment method has wide application prospects in the treatment and repair of central nerve damage caused by factors such as trauma, or peripheral neuritis or peripheral neurosensory abnormalities caused by factors such as viruses, diabetes and chemotherapeutic drugs.

To provide a biomarker, a diagnostic kit, and a method of assisting in diagnosis for the specific diagnosis of a group having specific disease state physiology in acute and chronic inflammatory demyelinating peripheral neuropathy with unknown autoantibody.SOLUTION: There are provided a biomarker, a diagnostic kit containing the same, and a method of assisting in diagnosis for using the same for diagnosis of inflammatory demyelinating polyneuropathy, including anti-LGI4 antibodies, or for determination of the efficacy of treatment, or the inflammatory demyelinating polyneuropathy being an autoimmune neuropathy.SELECTED DRAWING: None

The present application relates to adrenergic receptor ADRAC2 antagonists, to novel substituted heterocyclic carboxamides, to a method for the production thereof, to the use thereof alone or in combination for the treatment and / or prophylaxis of diseases and to the use thereof for producing medicaments for the treatment and / or prophylaxis of diseases, in particular for the treatment and / or prophylaxis of dyspnea, including sleep-induced dyspnea, including sleep-induced dyspnea, including sleep-induced dyspnea, including sleep-induced dyspnea, including sleep-induced dyspnea, including sleep-induced dyspnea. Such as central and obstructive sleep apnea, snoring (primary and obstructive snoring); dysphagia; peripheral and cardiovascular conditions, including diabetic microangiopathy; and peripheral and central nervous system disorders, including neurodegenerative and neuroinflammatory disorders.

The present application relates to novel substituted heterocyclic carboxamides, to a method for the production thereof, to the use thereof alone or in combination for the treatment and / or prophylaxis of diseases and to the use thereof for producing medicaments for the treatment and / or prophylaxis of diseases, in particular for the treatment and / or prophylaxis of dyspnea, including sleep-induced dyspnea, including sleep-induced dyspnea, including sleep-induced dyspnea. Such as central and obstructive sleep apnea, snoring (primary and obstructive snoring); dysphagia; peripheral and cardiovascular conditions, including diabetic microangiopathy; and peripheral and central nervous system disorders, including neurodegenerative and neuroinflammatory disorders.

The application relates to the technical field of targeted drugs, in particular to an organic compound and application of the organic compound in preparation of a PET probe for targeting 18kDa translocation protein and in pharmacy. 18 Or F. Compared with a conventional PET probe, the organic compound has the targeting TSPO characteristic, can be used for preparing the PET probe for targeting TSPO, is stable in in-vivo plasma metabolism, has lower non-specific uptake, and can be used for diagnosis, scientific research and drug preparation of neuroinflammation.

Provided is a composition for preparing a medicament for treating diabetic peripheral neuropathy. The pharmaceutical composition comprises cobra venom phospholipase A2, or a combination of cobra venom phospholipase A2 and at least one additional drug for treating diabetic peripheral neuropathy. The diabetic peripheral neuropathy is characterized by a slowdown in motor nerve conduction velocity and / or sensory nerve conduction velocity of a patient, and / or hypoesthesia or loss of sensation in both lower limbs. The pharmaceutical composition can be used to ameliorate the clinical symptoms described above in patients with diabetic peripheral neuropathy, and belongs to the field of biopharmaceuticals.

The invention belongs to the technical field of medicines, and particularly relates to a phenanthroindolizidine alkaloid compound and application thereof. The invention discloses two kinds of phenanthroindolizidine alkaloid compounds, namely (-)-(R)-13a alpha-secoxanthin and (-)-(R)-13a alpha-6-O-desmylanthin, which are derived from a traditional Chinese medicine cynanchum atratum, and discloses the obvious anti-neuritis activity of the phenanthroindolizidine alkaloid compounds for inhibiting the generation of nitric oxide. Animal experiments prove that by intraperitoneal injection of the (-)-(R)-13a alpha-secoxanthin and the (-)-13a alpha-6-O-desmylanthin, the autonomous movement ability of a depression mouse is remarkably improved, the exploration behavior of the mouse is recovered, the anxiety symptom of the mouse is relieved, and the despair behavior of the mouse is relieved. The invention provides a new lead compound for research and development of new antidepressant drugs.

The invention belongs to the technical field of biological medicines, and particularly relates to application of Chi3l1 as a target spot in preparation of a medicine for preventing or treating secondary brain injury after cerebral hemorrhage. By integrating space transcriptomics and a mononuclear RNA sequencing technology, the spatial heterogeneity and cell type specificity of gene expression in ICH afterbrain tissue are deeply analyzed, a group of astrocyte subgroups AST1 with neuritis existing around hematoma in the acute stage after cerebral hemorrhage is identified, Chi3l1 is determined as a key inflammatory effect factor of the AST1 subgroups, and the AST1 subgroups with neuritis are used as the key inflammatory effect factor of the AST1 subgroups. And the influence of the gene on the phenotypic transformation of astrocytes and microglial cells is verified. The discovery provides an important theoretical basis for developing a treatment strategy of targeting Chi3l1, and is expected to improve neuroinflammatory response and neurological dysfunction after ICH by regulating and controlling expression of the AST1 subgroup and Chi3l1, and opens up a new direction for treatment of ICH.

The present invention relates to a novel compound and a composition for preventing or treating neuroinflammatory brain diseases, the composition comprising same as an active ingredient and, more specifically, to a pharmaceutical composition for preventing or treating neuroinflammatory brain diseases and a food composition for preventing or ameliorating neuroinflammatory brain diseases, the compositions comprising a compound represented by Chemical Formula 1 as an active ingredient. The novel compound of the present invention can be effectively used to provide a therapeutic agent for preventing or treating neuroinflammatory brain diseases, a food for ameliorating neuroinflammatory brain diseases, or a functional food for enhancing a cognitive function.

The invention discloses a coumarin derivative with a structure as shown in a general formula (I) and application of the coumarin derivative. The solubility of the coumarin derivative with the structure in water is obviously improved, and the problem that an existing coumarin compound is low in solubility is solved. Researches show that the coumarin derivative shows relatively strong anti-inflammatory activity in the aspects of inhibiting inflammatory factors and promoting secretion of anti-inflammatory factors, and can be used for preparing medicines for preventing and treating central nervous inflammation or neurodegenerative diseases.

The present invention discloses a crotan-type diterpene compound, its preparation method, and application, relating to the field of pharmaceutical technology. The present invention extracts a crotan-type diterpene compound of novel structure from sage. The compound has significant inhibitory activity against neuronal inflammation, exhibits excellent anti-neuritis effects, and significantly inhibits inflammatory mediators. It can be developed as a therapeutic drug for neurodegenerative diseases.

The invention provides a cassane diterpenoid compound and an application of the cassane diterpenoid compound in preparation of an anti-neuroinflammation medicine. Six novel cassane diterpenoid compounds are separated from mysorethorn, and a preparation method of the six compounds is provided. According to the present invention, the inhibition effect of lipopolysaccharide (LPS)-induced BV-2 microglial cells on NO production is determined, and the six compounds have anti-neuroinflammatory activity, and particularly, the compounds 4 and 5 have good anti-inflammatory effect compared with other compounds, and have the potential of anti-neuroinflammatory drug preparation.

The invention provides a dendrobium officinale exosome composition loaded with miR-146a and miR-124 as well as a preparation method and application of the dendrobium officinale exosome composition loaded with miR-146a and miR-124. According to the present invention, the dendrobium officinale exosome has the antioxidant function, the miR-146a and the miR-124 have the synergistic anti-inflammatory function, the dendrobium officinale exosome provides the delivery carrier for the miR-146a and the miR-124, the stability and the anti-inflammatory function of the miR-146a and the miR-124 are improved, and the pharmaceutical composition EXE-miR-146a-124 for treating the neuritis and the related diseases thereof is finally developed. The invention not only provides a safe and efficient miRNA delivery system, but also endows the miRNA delivery system with neuroprotection and anti-inflammatory effects, and provides a brand new and naturally sourced intervention scheme for treatment of nervous system inflammatory diseases.

The invention discloses a posture and gait training auxiliary device and method suitable for vestibular neuritis patients in the technical field of medical instruments, the posture and gait training auxiliary device comprises guardrails, ground mats and eyeshades, the guardrails are arranged in two groups, and the ground mats are arranged in two groups. During treatment, the patient wears an eyeshade, walks according to a second foot type shown on a second ground mat and requires the patient to walk close to the front foot and the heel, when the feet of the patient are located at the position of the intelligent monitoring assembly on the second foot type, the induction lamp is turned on, the intelligent monitoring assembly starts to work, the intelligent monitoring assembly can adjust the timing range for 2-10 seconds, and the patient can walk on the second foot type. After the body of the patient is stabilized at the body position, the body does not shake or does not shake obviously, the patient walks next step. After the patient finishes four-stage training, the posture gait problem caused by chronic dizziness of the patient can be well improved. The method is low in cost per time, and a treatment place does not need to be in a hospital; the cost for self-rehabilitation treatment of a patient is low, the compliance is good, and the rehabilitation treatment effect can be well achieved.

The invention provides saCNTF-DSF-LNP composite nanoparticles as well as a preparation method and application of the saCNTF-DSF-LNP composite nanoparticles, and particularly relates to application of the saCNTF-DSF-LNP to preparation of medicines for treating diseases related to optic nerve injury. The method comprises the following steps: S1, preparing self-amplification CNTF RNA, and naming the self-amplification CNTF RNA as saCNTF; s2, preparing lipid nano particles entrapped with the disulfiram DSF; s3, quickly adding the ethanol phase containing the disulfiram DSF-lipid mixture into the aqueous phase containing the saCNTF, and mixing, so that the nanoparticles are formed by self-assembly; s4, purifying the nano particles by using an ultrafiltration centrifugal device to obtain saCNTF-DSF-LNP; the invention provides a preparation method and application of saCNTF-DSF-LNP, the saCNTF-DSF-LNP can inhibit neuroinflammation driven by acute pyroptosis, and continuous neurotrophic support is provided for RGC survival and long-term axon regeneration; according to saCNTF-DSF-LNP, continuous expression of CNTF is achieved through saRNA, efficient targeted delivery is achieved by means of LNP so as to reduce off-target toxicity of DSF, and a new treatment strategy is provided for neuritis and degenerative diseases.

The invention relates to the technical field of biological medicines, and particularly discloses application of oridonin in preparation of anti-neuritis medicines. The oridonin disclosed by the invention can be used for inhibiting neuroinflammation and inhibiting programmed death of neuronal cells, so that neurons are protected. Chemical structural formula of oridonin is as follows: # imgabs0 #

Provided herein are multi-chain chimeric polypeptides and their use in reducing neuroinflammation in a subject.

The present disclosure provides single or double stranded interfering RNA molecules (e.g., siRNAs) that target a transmembrane 4 domain AGA (MS4A6A) gene. The interfering RNA molecule may contain a specific pattern of nucleoside modification and inter-nucleoside linkage modification as a pharmaceutical composition comprising the interfering RNA molecule. The siRNA molecule may be a branched siRNA molecule, such as a two-branched, three-branched or four-branched siRNA molecule. The disclosed siRNA molecules may also be characterized by a 5 '-phosphorus stabilizing moiety and / or a hydrophobic moiety. In addition, the present disclosure provides methods for delivering the siRNA molecules of the present disclosure to a subject, such as the central nervous system of a subject identified as having a neuroinflammatory disease (e.g., Alzheimer's disease).

The present disclosure provides single- or double-stranded interfering RNA molecules (e.g., siRNA) that target a SiglecS (CD33) gene. The interfering RNA molecules may contain specific patterns of nucleoside modifications and internucleoside linkage modifications, as pharmaceutical compositions including the same. The siRNA molecules may be branched siRNA molecules, such as di-branched, tri-branched, or tetra-branched siRNA molecules. The disclosed siRNA molecules may further feature a 5′ phosphorus stabilizing moiety and / or a hydrophobic moiety. Additionally, the disclosure provides methods for delivering the siRNA molecule of the disclosure to the central nervous system of a subject, such as a subject identified as having a neuroinflammatory disease (e.g., Alzheimer's disease).

The application discloses a sesquiterpene dimer and a preparation method and application thereof, and belongs to the technical field of natural compound extraction. According to the preparation method, dried sesquiterpene dimers are extracted by refluxing with 95% ethanol, and then petroleum ether and ethyl acetate are used for extraction to obtain an extract, which can be obtained by column chromatography and semi-preparative high performance liquid chromatography, so that the method is simple, time and labor are saved, and the yield is higher. The obtained sesquiterpene dimers have high anti-neuritis activity, and have important application prospects for developing new drugs for treating senile dementia.

The invention provides aaptamine alkaloid as well as a preparation method and application of the aaptamine alkaloid. The aaptamine alkaloid has a structure as shown in a formula I which is described in the specification. The aaptamine alkaloid can significantly inhibit the generation of LPS-induced BV2 cell NO, and inhibit the expression of inflammatory factors IL-6, IL-1beta and TNF-alpha, so that the aaptamine alkaloid has an anti-neuritis effect. # imgabs0 #

The present invention relates to novel compounds, more particularly to a class of substituted 4-aryl-pyridine compounds, pharmaceutically active salts, prodrugs and analogues thereof. The compounds described herein are more particularly selective adenosine receptor ligands wherein said ligands may be used for the treatment or prophylaxis of disorders including cardiovascular disorders, respiratory disorders, inflammatory and neuroinflammatory disorders, among others.